防治心力衰竭新药临床应用及研究进展

Clinical research and application progress of new drugs for the treatment of heart failure

心力衰竭(heart failure,HF)是全球的公共卫生问题,是多种心血管疾病的终末阶段,HF患者面临着高死亡率的威胁,且因反复住院及活动耐受差,严重影响生活质量。一线药物如利尿剂、肾素血管紧张素醛固酮系统(renin-angiotensin-aldosterone system,RAAS)抑制剂和β受体拮抗剂(beta-receptor blockers,BB)等使各类HF患者获益,但临床应用时产生的电解质紊乱、干咳、血管性水肿、心律失常和肾功能损伤等不良反应时有发生;同时药物种类的局限为心力衰竭药物治疗带来桎梏。因此,国内外围绕HF的新药研发一直在开展。本文就近5年在中国上市的防治HF新药临床应用及其在各期临床研究取得的进展进行综述,旨在明确HF新药临床应用价值与前景,为临床HF药物治疗提供新的思路。

Heart failure(HF),as the end stage of many cardiovascular diseases,is a major public health problem globally.High mortality and high rate of hospital readmissions among patients with HF severely worsen the quality of life.First-line drugs like diuretics,renin-angiotensin-aldosterone system(RAAS)inhibitors,and beta-receptor blockers(BB)benefit all kinds of HF patients,but they sometimes cause adverse events like electrolyte disturbance,dry cough,angioedema,arrhythmia and renal function damage.Meanwhile,the limitation of the drug types brings a shackle to the treatment of HF.Therefore,research and development of new drugs for the treatment of HF have been carried out domestically and overseas.This review highlights several new HF drugs that has been marketed in China within the 5 years,aiming to summarize their clinical application and the research progress.Our findings provide new treatment strategies for HF.